ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

Search

Diversified Healthcare Trust

Ouvert

SecteurIndices

6.6 -1.79

Résumé

Variation du prix de l'action

24h

Actuel

Min

6.6

Max

6.82

Chiffres clés

By Trading Economics

Revenu

143M

-21M

Ventes

-9.1M

380M

BPA

-0.063

Rendement du dividende

0.6

Marge bénéficiaire

-5.591

EBITDA

190M

136M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.52% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.60%

4.60%

Prochains Résultats

4 mai 2026

Date du Prochain Dividende

14 mai 2026

Date du Prochain Détachement de Dividende

21 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

114M

1.6B

Ouverture précédente

8.39

Clôture précédente

6.6

Sentiment de l'Actualité

By Acuity

23%

77%

1 / 26 Classement par Indices

Score Technique

By Trading Central

Confiance

Bullish Evidence

Diversified Healthcare Trust Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mars 2026, 23:31 UTC

Actions en Tendance

Stocks to Watch: Nike, RH, NCino

31 mars 2026, 22:35 UTC

Résultats

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 avr. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mars 2026, 23:50 UTC

Acquisitions, Fusions, Rachats

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mars 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mars 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mars 2026, 23:21 UTC

Résultats

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mars 2026, 23:14 UTC

Market Talk
Résultats

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mars 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss Widens >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mars 2026, 21:46 UTC

Acquisitions, Fusions, Rachats

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mars 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mars 2026, 21:35 UTC

Résultats

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mars 2026, 21:33 UTC

Résultats

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mars 2026, 21:32 UTC

Résultats

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mars 2026, 21:28 UTC

Résultats

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mars 2026, 21:26 UTC

Résultats

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mars 2026, 21:25 UTC

Résultats

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mars 2026, 21:24 UTC

Market Talk
Résultats

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mars 2026, 21:22 UTC

Résultats

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mars 2026, 21:22 UTC

Résultats

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mars 2026, 21:21 UTC

Résultats

Nike's Digital Channel Still Too Promotional, CFO Says

31 mars 2026, 21:20 UTC

Résultats

Nike CEO: Converse Remains Important to Portfolio

Comparaison

Variation de prix

Diversified Healthcare Trust prévision

Objectif de Prix

By TipRanks

9.52% hausse

Prévisions sur 12 Mois

Moyen 7.25 USD  9.52%

Haut 8.5 USD

Bas 6 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.34 / 3.02Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

1 / 26Classement par Indices

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Diversified Healthcare Trust

DHC is a real estate investment trust, or REIT, focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum by care delivery and practice type, by scientific research disciplines and by property type and location. As of December 31, 2023, DHC's approximately $7.2 billion portfolio included 371 properties in 36 states and Washington, D.C., occupied by approximately 500 tenants, and totaling approximately 8.6 million square feet of life science and medical office properties and more than 27,000 senior living units. DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with over $41 billion in assets under management as of December 31, 2023 and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, MA.
help-icon Live chat